Literature DB >> 23606704

Measurement error in the assessment of radiographic progression in rheumatoid arthritis (RA) clinical trials: the smallest detectable change (SDC) revisited.

V Navarro-Compán1, D van der Heijde, Harris A Ahmad, Colin G Miller, R Wolterbeek, R Landewé.   

Abstract

OBJECTIVES: To evaluate if the mean smallest detectable change (SDC) of multiple time intervals using the Bland & Altman (B&A) levels of agreement (LoA) method is an appropriate surrogate for the generalisability analysis method for estimating the overall SDC of radiological progression in rheumatoid arthritis (RA) trials. Secondly, to compare the SDC based on 95% LoA with the SDC based on 80% LoA, and to investigate the association between SDC and baseline damage and progression.
METHODS: Fifteen datasets from randomised controlled trials in RA were scored by 13 experienced readers as pairs according to the modified Sharp/van der Heijde method. The SDC using the 95% and 80% LoA and the generalisability methods was calculated.
RESULTS: 21 295 radiographic time points from 7643 patients were included. The mean (range) SDC for the LoA and the generalisability methods was 3.1 (2.3-4.3) and 3.2 (2.3-4.6) units, respectively. The mean ± SD difference between the two methods was -0.13 ± 0.28. The mean SDC including all intervals (n=31) was 3.0 ± 0.7 for 95% LoA and 2.0 ± 0.4 for 80% LoA. No relationship was observed between baseline damage and the SDC, whereas the SDC increased with increasing radiological progression.
CONCLUSIONS: The mean of the interval SDCs obtained by the simple LoA method is a valid surrogate for the SDC obtained by complex generalisability methods. The SDC depends on the level of radiographic progression rather than on the level of absolute damage. In addition, the use of an SDC based on 80% rather than on 95% LoA is proposed.

Entities:  

Keywords:  Outcomes research; Quality Indicators; Rheumatoid Arthritis

Mesh:

Year:  2013        PMID: 23606704     DOI: 10.1136/annrheumdis-2012-202939

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.

Authors:  Noortje van Herwaarden; Aatke van der Maas; Michiel J M Minten; Frank H J van den Hoogen; Wietske Kievit; Ronald F van Vollenhoven; Johannes W J Bijlsma; Bart J F van den Bemt; Alfons A den Broeder
Journal:  BMJ       Date:  2015-04-09

2.  The FAt Spondyloarthritis Spine Score (FASSS): development and validation of a new scoring method for the evaluation of fat lesions in the spine of patients with axial spondyloarthritis.

Authors:  Susanne Juhl Pedersen; Zheng Zhao; Robert G W Lambert; Stephanie Wichuk; Mikkel Østergaard; Ulrich Weber; Walter P Maksymowych
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

3.  Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis.

Authors:  Susanne J Pedersen; Stephanie Wichuk; Praveena Chiowchanwisawakit; Robert G Lambert; Walter P Maksymowych
Journal:  Arthritis Res Ther       Date:  2014-04-22       Impact factor: 5.156

4.  Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study.

Authors:  Gülşah Akdemir; Marije K Verheul; Lotte Heimans; Kirsten V C Wevers-de Boer; Yvonne P M Goekoop-Ruiterman; Maikel van Oosterhout; Joop B Harbers; Casper Bijkerk; Gerda M Steup-Beekman; Leroy R Lard; Tom W J Huizinga; Leendert A Trouw; Cornelia F Allaart
Journal:  RMD Open       Date:  2016-02-15

5.  Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials.

Authors:  Edward C Keystone; Harris A Ahmad; Yusuf Yazici; Martin J Bergman
Journal:  Rheumatology (Oxford)       Date:  2020-08-01       Impact factor: 7.580

6.  Test-retest reliability of outcome measures: data from three trials in radiographic and non-radiographic axial spondyloarthritis.

Authors:  Anne Boel; Victoria Navarro-Compán; Désirée van der Heijde
Journal:  RMD Open       Date:  2021-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.